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Abstract
Von Hippel-Lindau syndrome (VHL) is a familial neoplastic condition seen in approximately 1 in 36,000 live births. It is caused
by germline mutations of the tumor suppressor gene VHL, located on the short arm of chromosome 3. While the majority of
the affected individuals have a positive family history, up to 20% of cases arise from de novo mutations. VHL syndrome is
characterized by the presence of benign and malignant tumors affecting the central nervous system, kidneys, adrenals, pancreas,
and reproductive organs. Common manifestations include hemangioblastomas of the brain, spinal cord, and retina; pheochromo-
cytoma and paraganglioma; renal cell carcinoma; pancreatic cysts and neuroendocrine tumors; and endolymphatic sac tumors.
Diagnosis of VHL is prompted by clinical suspicion and conﬁrmed bymolecular testing. Management of VHL patients is complex
and multidisciplinary. Routine genetic testing and surveillance using various diagnostic techniques are used to help monitor
disease progression and implement treatment options. Despite recent advances in clinical diagnosis and management, life
expectancy for VHL patients remains low at 40–52 years. This article provides an overview of the major clinical, histological,
and radiological ﬁndings, as well as treatment modalities.
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Introduction
Von Hippel-Lindau (VHL) syndrome is an autosomal-
dominant, multi-organ, familial neoplastic syndrome, which
is caused by genetic aberrations of the tumor suppressor gene
VHL.Germlinemutations of the VHLgene predispose affected
individuals to the development of benign andmalignant tumors
in several systems including the central nervous system (CNS),
and visceral organs such as the kidneys, pancreas, adrenals,
and reproductive organs. The most common VHL-associated
tumors are hemangioblastomas involving brain, spinal cord,
and retina; clear cell renal cell carcinoma (RCC); pheochromo-
cytomas and paragangliomas; and pancreatic neuroendocrine
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tumors (PNETs) (1). Other ﬁndings include endolymphatic sac
tumors (ELSTs) and papillary cystadenomas of the epididymis
and broad ligament. VHL affects 1 in 36,000 live births and its
inheritance pattern occurs in an autosomal dominant fashion,
with a penetrance of over 90% by the age of 65. Early manifes-
tations of VHL syndrome occur in the second decade of life and
nearly 50% of patients are symptomatic at presentation. Cere-
bellar hemangiomas are the most common presenting symptom
of VHL (2). Life expectancy of VHL patients was previously
between 40 and 52 years, an average of 59.4 years for males
and 48.4 years for females (3). VHL-related mortality is com-
monly due to complications related to RCC and CNS tumors.
A brief overview of genetic and molecular biology
VHL gene is a tumor suppressor gene, located on the short
arm of chromosome 3. It encodes for pVHL, a tumor sup-
pressor protein involved in cellular signaling pathways.
There are two isoforms of pVHL: pVHL30 and pVHL19.
The pVHL30 isoform is composed of 213 amino acids. The
smaller isoform, pVHL19, results from alternate translation
initiation site in the open reading frame of codon 54, resulting
in protein made of 160 amino acids, lacking the ﬁrst 53 resi-
dues (4). Both isoforms are important for tumor suppressor
effects of the VHL gene. Inactivating gene deletions, frame-
shifts, and missense mutations of the gene have been impli-
cated in VHL syndrome. While the majority of VHL cases
are familial, 20% of VHL cases are due to sporadic mutation.
Most patients with VHL syndrome inherit a germline muta-
tion of the VHL gene from affected parents and a wild-type
gene from the unaffected parent. In affected individuals,
germline mutations of the gene are present in all cell types
of the body (ﬁrst hit); however, only those cell types with
a somatic inactivation of the normal allele are prone to
tumor formation (second hit) (5). Thus, VHL follows
Knudson’s two-hit hypothesis of hereditary tumorigenesis
as in retinoblastoma.
The VHL gene product, pVHL, plays an important role in
the regulation of hypoxia pathways through the transcription
factor hypoxia-inducible factor (HIF), a heterodimeric mole-
cule composed of alpha and beta subunits. The pVHL protein
forms part of the VCB-CUL2 complex which is involved in
ubiquitin-mediated degradation of HIF, and the tumor sup-
pressive effects of functional pVHL are believed to be exerted
through degradation of HIF (6). In normoxic environment,
VCB-CUL2 complex binds to the alpha subunit of HIF,
polyubiquitinates it, and marks for degradation. However,
hypoxic conditions or functional loss of pVHL leads to stabi-
lizations of HIF-α molecules, leading to sustained expression
of pro-tumorigenic molecules including vascular endothelial
growth factor (VEGF), platelet-derived growth factor (PDGF),
erythropoietin, and transforming growth factor alpha (TGF-a)
(7, 8). Subsequently, the upregulated target factors lead to
rapid proliferations, tumorigenesis, and angiogenesis. HIF-
independent mechanisms of VHL-mediated tumorigenesis
include regulation of extracellular matrix, apoptosis, tran-
scription, and stabilizing of microtubules (9, 10).
Patients can have variable presentations; the diagnosis is
often conﬁrmed by positive family history and presence of
one VHL-associated tumor. In cases with no known history
of VHL, the presence of multiple tumors is needed for diag-
nosis since approximately 20% of cases are the result of de
novo mutations. Speciﬁc genotype–phenotype correlations
in affected families led to the classiﬁcation of VHL subtypes
into types 1 and 2 (Table 1), primarily based on the presence
of pheochromocytoma (11). Type 1 disease has a very low
risk of pheochromocytomas. Type 2 VHL is further categor-
ized into type 2a (low risk of RCC), type 2b (high risk of
RCC), and type 2c which only presents with pheochromocy-
tomas (12). Management of VHL-associated tumors requires
multidisciplinary approach, and advances in genetic testing
have led to early diagnosis of the syndrome. Various screen-
ing guidelines are in place to help monitor the progress of the
different manifestation of VHL since early interventions can
Table 1. Classiﬁcation of Von Hippel-Lindau Syndrome
Type Clinical ﬁndings Mutations
Type 1 (decreased risk for PCC)
Retinal and CNS HB, RCC, pancreatic
cysts, and neuroendocrine tumors
Truncating or missense mutations
Type 2 (increased risk for PCC)
Type 2A (low risk of RCC) PCC, retinal HB, CNS HB Missense mutation
Type 2B (high risk of RCC)
PCC, RCC, Retinal HB, CNS HB,
pancreatic cyst, and neuroendocrine
tumors
Type 2C PCC only
Adapted from Refs. (6) and (15).
HB, hemangioblastoma; PCC, pheochromocytomas; RCC, renal cell carcinoma.
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help prevent adverse outcomes (Table 2). Inheritance of the
VHL syndrome occurs in an autosomal dominant fashion,
and more than 300 germline mutations have been found in
familial VHL cases. Hence, patients present with a wide
spectrum of manifestations in the CNS, kidneys, adrenal
glands, pancreas, and reproductive organs. An overview
of the clinical features of these manifestations and their
management is presented below.
Table 2. Surveillance of VHL manifestations
Age Screening
Ages 1 to 4
Annually
• Eye or retinal examination with indirect ophthalmoscopy
• Thorough clinical examination to look for signs of neuro-
logical disturbance, nystagmus, white pupil, and abnorm-
alities in blood pressure, or hearing or vision
Ages 5 to 15
Annually
• Physical examination and neurological assessment for
blood pressure (lying and standing), hearing issues, neuro-
logical disturbance, nystagmus, strabismus, white pupil,
and other signs
• Eye or retinal examination with indirect ophthalmoscopy.
• Abdominal ultrasonography annually from 8 years or ear-
lier if indicated.
• Test for plasma metanephrines or urinary metanephrines
using 24-h urine test
Every 2 to 3 years
• Complete audiology assessment
• If repeated ear infections, MRI with contrast of the inter-
nal auditory canal for a possible endolymphatic sac tumor
(ELST)
Ages 16 and above
Annually
• Thorough physical examination
• Eye or retinal examination with indirect ophthalmoscopy
• Ultrasound and MRI scan of the abdomen with and with-
out contrast to assess kidneys, pancreas, and adrenals at
least every other year
• Test for plasma metanephrines or urinary metanephrines
using 24-h urine test
Every 2 years
• MRI with contrast of brain, cervical, thoracic, and lum-
bar spine to rule out both ELST and hemangioblastomas
• Audiology assessment
During pregnancy
• Regular retinal checkup to anticipate potentially more
rapid progression of lesions
• Test for pheochromcytoma in early, mid, and late preg-
nancy
• During the fourth month of pregnancy, MRI (without
contrast). If known retinal, brain, or spinal lesions, con-
sider cesarean section
Adapted from Refs. (8) and (19).
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Central nervous system hemangioblastomas
General features
CNS hemangioblastomas are the most common tumors in
VHL syndrome affecting 60–80% of all patients (Table 3)
(1, 13, 14). On average, the age of presentation is 33. The
tumors are benign but are a major cause of morbidity and
mortality due to mass effect on nearby CNS structures.
These hemangioblastomas can be found in the cerebellum
(16–69%), brainstem (5–22%), spinal cord (13–53%), cauda
equina (11%), or supratentorial region (1–7%) (5, 14). Due
to tumor growth, cysts and/or subsequent edema formation,
the mass effect occurs within the CNS contributing to the
clinical symptoms (5, 14, 15). Tumors can exhibit linear
growth, exponential growth, or periods of ﬂuctuation (14).
When observed for more than 5 years, over 50% of hemangio-
blastomas will increase in size (16, 17). Any given patient may
have various tumors that uniquely grow at different rates and
patterns. High tumor burden is linked to partial germline
mutation and male sex (5, 14).
Radiological and histological findings
The modality of choice for detecting CNS hemangioblasto-
mas is contrast-enhanced magnetic resonance (MR) imaging
(5, 6, 14–18). Lesions as small as 2 mm will appear as enhan-
cing lesions on T1-weighted images. On gross appearance,
hemangioblastomas can be described as red vascular masses
that reside within a layer of the thin capsule. The tumors
are comprised of polygonal-shaped stromal cells ﬂanked
with several vascular structures (5). The blood vessels that
supply larger hemangioblastomas are derived from migrating
endothelial cells from nearby normal tissue. The polygonal
stromal cells originate from multipotent hemangioblasts,
which also differentiate into de novo tumor blood vessels (4)
(Figure 1).
Management
Craniospinal lesions are surgically resected safely and are
often curative. Since CNS hemangioblastomas can grow at
different sites and at irregular times, the approach to resect
is withheld until patients are symptomatic (17). Asympto-
matic lesions are monitored with annual imaging. Preopera-
tive arterial embolization is indicated for extensive tumors
to control tumor vascularity (19). Stereotactic radiosurgery
(SRS) has been used to control solid, small CNS lesions
(<3 cm diameter) in inoperable cases to prevent complica-
tions associated with microsurgery. Some studies report
favorable short-term tumor control rates with SRS; however,
there is no long-term beneﬁts as SRS-treated tumors continue
to grow at similar rates compared to the natural progression
of the hemangioblastomas (20). Future studies are needed to
assess the potential long-term effects and beneﬁts of SRS.
Retinal hemangioblastomas
General features
Retinal hemangioblastomas arise frequently in VHL patients.
They are seen in as many as 60% of patients (Table 3) (7, 14).
Although not the most common tumor in VHL, they are
often the ﬁrst manifestation. The median age of onset is 21,
which is the lowest among the other clinical features (5, 14).
These retinal lesions are symptomatic at presentation. All
patients who present with one retinal hemangioblastoma
will likely develop bilateral lesions by age 56 (14). Complica-
tions of retinal hemangioblastomas include blindness or
severe visual deﬁcits in 5–8% of VHL patients (7, 14). The
disease may occur at the periphery or optic nerve. Both
can lead to symptoms as a result of the accumulation of sub-
retinal ﬂuid and development of hard exudates in the macula.
Worse visual outcomes are associated with early age of onset
Table 3. Frequency of lesions and average age range of presentation in VHL patients
Clinical Feature
Average (range) of
presentation (years)
Frequency (%) Reference
CNS hemangioblastoma 30 (9–78) 60–80% 1
Retinal hemangioblastoma 25 (1–67) 49–62% 4, 6
Endolymphatic sac tumors 31 (12–50) 6–15% 7, 15
Renal cell carcinoma or cysts 39 (16–67) 30–70% 6
Pheochromocytoma 30 (5–58) 10–20% 6
Pancreatic neuroendocrine
tumors or cysts
36 (1–70) 35–70% 8, 15
Epididymal cystadenomas Unknown (16–40) 25–60% 6, 15
Broad ligament cystadenomas Unknown (16–46) Unknown 8
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of ocular disease, bilateral involvement, and missense muta-
tions in VHL (7, 14, 17).
Radiological and histological findings
Retinal hemangioblastomas resemble CNS hemangioblasto-
mas grossly and histologically. The level of gliosis and
hemorrhage may indicate the severity of the lesion. The
ophthalmoscope in conjunction with pharmacological dila-
tion of the iris allows for the identiﬁcation of most retinal
tumors. Fluorescein angiography is used to evaluate macular
function associated with new lesions in the periphery or optic
nerve. Screening exams should be conducted annually begin-
ning at age 1, with dilated fundoscopy (7).
Management
Management of capillary retinal hemangioblastomas includes
laser photocoagulation, cryotherapy, and diathermy depending
on the location and size of the lesions. Photocoagulation is
used for controlling small capillary hemangiomas growing in
the posterior part of the retina and has been shown to be
very effective in treating tumors that are 1.5 mm or smaller
(7). Response rates to direct laser coagulation have been
reported to be more than 90%. Cryotherapy is indicated
in managing retinal hemangiomas located anteriorly and is
most effective in tumors with less than 3 mm in diameter.
Vitreoretinal surgery is utilized in cases where retinal detach-
ment due to traction occurs and exudation is present. To
prevent blindness, hemangioblastomas near the optic nerve
are treated with intravitreal anti-VEFG therapy to control
growth and help ameliorate edema and exudate formation
(14). External beam radiotherapy can be performed in the
treatment of refractory cases.
Endolymphatic sac tumors
General features
ELSTs develop from endolymphatic epithelium within the
vestibular aqueduct (16). The endolymphatic system plays
a role in the production and resorption of endolymph
which is found within the cochlea and semicircular canals.
These tumors are found in 6–15% of VHL patients;
however, they are rare in the general population (Table 3)
(6, 14). They generally appear around 31 years of age.
They are benign tumors that do not metastasize but may
be locally aggressive (6). Patients may present with ear
fullness, disequilibrium, and hearing loss. Larger lesions
(>3 cm) can disturb the facial nerve resulting in facial
paresis (14, 16).
Radiological and histological findings
Diagnosis of ELSTs through radiologic examination should
include the use of precontrast and postcontrast computed
tomography (CT) and magnetic resonance imaging (MRI)
(5, 6, 14). The internal auditory canal is the target location.
On CT, these tumors exhibit similar intensity as the brain
parenchyma; however, there may be focal areas of low and
high attenuation. Centered within the endolymphatic duct,
large tumors are visualized as expanding into the temporal
bones on CT (5). On precontrast T1-weighted MRI, the level
of intensity may be either homogeneous or heterogeneous.
Postcontrast T1-weighted MRI will show variable patterns of
enhancement or homogeneity. To aid the assessment of hearing
loss, audiograms are employed to supplement CT and/or MRI
imaging (16). ELSTs are richly vascular, often eroding the
nearby temporal bone. Histologically, these lesions are papil-
lary cystic glandular neoplasms with variable patterns. Due
to their association with local bone erosion and adenomatous
appearance, these tumors were formerly referred to as low-
grade adenocarcinomas (5, 14, 16). When endolymphatic
tumors are small, they can be entirely found within the endo-
lymphatic sac. Conversely, they invade and erode the temporal
bone when they are large (16).
Management
Surgical resection is the mainstay therapy for ELSTs that are
detectable on radiographs in order to prevent sensorineural
hearing loss and treat audiovestibular symptoms. Complete
resection is also indicated for patients with an evidence of
intralabyrinthine hemorrhage, but no visible tumors on ima-
ging studies as hemorrhage indicate presence of microscopic
ELSTs (15). Most patients who undergo total resection of
tumors retain their hearing ability. Rates of recurrence are
minimal in the majority of cases, approximately 3% (21).
Radiation therapy may have a role in unresectable tumors;
however, not enough studies have been conducted to assess
its efﬁcacy.
Figure 1. (A) Axial T1 postcontrast images demonstrate an
enhancing mural nodule (white arrow) with accompanying
cyst (*) in the right cerebellar hemisphere exerting a mass
effect upon the midline and fourth ventricle (double white
arrow). (B) Hematoxylin-eosin staining showing scattered
large hyperchromatic nuclei, vacuolated cells, and multiple
capillaries which are classic features of the cellular type of
hemangioblastoma.
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Renal cell carcinoma and renal cysts
General features
Renal manifestations of VHL include benign renal cysts and
clear cell carcinoma (1, 6). Multiple bilateral renal cysts are
found on screening in 50–70% of VHL patients (Table 3)
(14). RCC may affect up to 30% of VHL patients. They are
rarely the ﬁrst sign of VHL. Renal cysts are asymptomatic,
and unlike autosomal dominant polycystic kidney disease,
the incidence of chronic renal failure is low. Bilateral RCCs
and renal cysts present in the third or fourth decade of life
in these patients (22). Up to 70% of VHL patients develop
RCC by 60 years of age; RCC is the leading cause of mortal-
ity in this group of patients (14). VHL renal lesions range
from simple cysts to entirely solid lesions (6). Clinical ﬁndings
include renal mass with ﬂank pain or hematuria (1, 6, 14).
Simple renal cysts are generally asymptomatic, while complex
cysts may become solid renal masses. Renal function can be
preserved despite having multiple cysts (16).
Radiological and histological findings
Serial imaging of the kidneys is useful in detectingRCCbecause
it often remains asymptomatic for long periods of time (5, 6,
14, 16). Simple renal cysts in VHL syndrome are usually
asymptomatic and rarely need intervention. More complex
cysts require monitoring as they may have some solid compo-
nents of RCC. Diagnosis during the presymptomatic stage
has the potential to improve outcomes. Abdominal CT with
contrast is the gold standard for diagnosis of renal lesions of
VHL (5, 14). It allows clinicians to quantify the size and the
number of tumors and cysts. CT can differentiate simple cysts
from complex cysts (14). Abdominal MRI is also accurate in
this regard. RCC and cysts in VHL are the clear cell type (5).
VHL-related RCC is histologically similar to sporadic clear
cell carcinoma. They often have low-grade histology (Figure 2).
Management
RCCs are typically detected on routine screening, and no
intervention is necessary for tumors less than 3 cm in diameter.
Partial nephrectomy is the treatment of choice for tumors
that have reached the 3 cm threshold to reduce the risk
of metastasis while maintaining kidney function. Nephron
sparing surgeries on lesions greater than 3 cm have 10-year
cancer survival rates as high as 81% with preservation of
renal function (14). Percutaneous and laparoscopic radiofre-
quency ablation therapy has been proven to be effective in
treating smaller tumors (<3 cm) with low complication rates
(23). However, lesions ablated with radiofrequency need
frequent monitoring and intervention.
Pheochromocytomas
General features
Pheochromocytomas occur in up to 20% of VHL patients
(Table 3). The hereditary syndromes, subtypes, susceptibility
genes, and sites of pheochromocytomas are summarized in
Table 4. They can be bilateral and occasionally multifocal.
Pheochromocytomas usually present in the second decade
of life in VHL patients and rarely transform into malig-
nant tumors. These tumors produce catecholamines, such as
excessive norepinephrine, causing hypertension, tachycardia,
palpitations, headaches, sweating, pallor, and nausea (5, 13).
Radiological and histological findings
The diagnosis of pheochromocytoma is based on biochemical
laboratory and imaging studies (5, 13, 14). Functional labora-
tory tests are useful especially when imaging does not show
tangible evidence of a lesion. Plasma free metanephrines is
the most sensitive method (97% sensitivity) for detecting
pheochromocytoma more so than the 24-h urinary measure-
ment of catecholamines which can yield false negative results
(14). Postcontrast abdominal CT imaging is sensitive in
detecting adrenal and extra-adrenal pheochromocytomas.
Contrast-enhanced MRI of the abdomen is between 90%
and 100% sensitive in the detection of these tumors and is the
preferred modality compared to CT. Identiﬁcation of extra-
adrenal tumors may beneﬁt from meta-iodobenzylguanidine
(MIBG) scintigraphy (5, 6, 13, 14). On histology, classic pattern
Figure 2. (A) Axial T2 weighted images show a T2 hypoin-
tense lesion in the posteromedial aspect of the midportion
of the right kidney (white arrow). (B) Axial T1 postcontrast
images show enhancement of the lesion (dashed white arrow)
indicating a solid renal mass such as renal cell carcinoma.
(C) Low-power- and (D) high-power-hematoxylin-eosin stain-
ing showing a typical picture of clear cell renal cell carcinoma
with nests of clear cells surrounded by intricately branching
vascular septa.
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is seen as small nests (zellballen) of neuroendocrine cells (chief
cells) with interspersed small blood vessels. However, numerous
variant and combined patterns exist, including diffuse growth,
large zellballen, spindle cells, cell cords, etc. (Figure 3).
Management
The preferred treatment for pheochromocytomas is surgical
resection with part adrenalectomy by laparoscopic approaches.
Perioperativemanagement of pheochromocytomas with a com-
bination of alpha-adrenergic and beta-adrenergic blockade is
necessary to prevent catecholamine-mediated life-threatening
complications such as cardiac arrhythmias, hypertensive crisis,
and myocardial infarction. Pharmacological intervention for
10–14 days is required prior to surgery. Early cortical-sparing
partial adrenalectomy has shown low recurrence rates in a
follow-up of 36 VHL patients with pheochromocytomas (24).
Pancreatic neuroendocrine tumors and cysts
General features
About 35–70% of patients with VHL present with pancreatic
ﬁndings (Table 3). Up to 72% of VHL patients will have
pancreatic cysts on autopsy (5, 6, 9–11, 13, 14). There are
usually multiple cysts that present without symptoms. Serous
cystadenomas and neuroendocrine tumors are other manifes-
tations of pancreatic lesions in VHL syndrome (5). In 12%
of patients, pancreatic cysts may be seen as the only sign
of VHL (13, 14). Neuroendocrine tumors can become malig-
nant and metastatic in 8% of patients (14). Due to the repla-
cement of pancreatic parenchyma, cysts and cystadenomas
of the organ can cause exocrine or endocrine deﬁciency
(5, 6). Compression of nearby structures (e.g., the intestines
or bile duct) can lead to symptoms (14, 16). Neuroendocrine
tumors of the pancreas are rarely the cause of morbidity and
mortality. However, tumor conversion to malignancy or
metastasis may lead to a poor prognosis. High tumor burden
is associated with size greater than 3 cm and growth that
doubles in less than 500 days (14, 16).
Radiological and histological findings
Pancreatic cysts are often clinically silent; therefore, routine
imaging is important for diagnosis in VHL patients (14). On
postcontrast CT imaging, a PNET can be seen as an enhancing
mass (5, 6). Once the presence of the tumor is established, MRI
can help conﬁrm the diagnosis. Endoscopic ultrasound and
somatostatin receptor scintigraphy are additional options for
detecting these lesions (5, 14). FDG positron emission tomogra-
phy (PET) has been utilized to identify neuroendocrine tumors
that are not visible by CT. PNETs are well circumscribed and
encapsulated in nature. From a histological standpoint, these
tumors are derived from pancreatic islet cells. Originally, they
were called islet cell tumors. Using immunohistochemistry, the
Table 4. Hereditary syndromes and subtypes of pheochromocytoma
Syndrome Susceptibility gene Tumor location Reference
MEN type 2A, 2B RET Adrenal (bilateral) 26
VHL type 2A, 2B, 2C VHL Adrenal (bilateral) 4
Neuroﬁbromatosis type 1 NF1 Adrenal 26
Familial paraganglioma
syndrome type 1, 3, 4
SDHA, SDHB, SDHC
Head and neck, adrenal,
extra-adrenal (i.e., gastroin-
testinal stromal tumor)
14, 26
Familial pheochromocytoma Chr 2, 16 Adrenal, extra-adrenal 26
Figure 3. (A) Coronal Single-shot fast spin echo (SSFSE) image
of the abdomen shows a high signal lesion (white arrow) within
the medial limb of the left adrenal gland. (B) Coronal T1 post-
contrast image shows a homogeneously enhancingmass (dashed
white arrow) consistent with pheochromocytoma. (C) and (D)
Hematoxylin-eosin staining showingnests of tumor cells (zellbal-
len growth pattern) surrounded by a discontinuous layer of sus-
tentacular cells and ﬁbrovascular stroma intermixed with blood.
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neoplastic cells stain positive for pancreatic and gastrointestinal
hormones (5). Pancreatic cysts and cystadenomas consist of
clear glycogen-rich epithelial cells and ﬁbrous stroma (Figure 4).
Management
Pancreatic cysts do not require surgical intervention;
however, surgical compression is indicated for patients with
obstructive symptoms. PNETs with a potential for metastatic
disease are resected with enucleation by Whipple’s procedure
or partial pancreatectomy depending on the size and location
of the tumor (5). Resection criteria involve tumor size greater
than 3 cm, a pathogenic variant in exon 3, and tumor with a
doubling growth rate in less than 500 days, all of which
increases the risk of metastasis (25).
Epididymal cystadenomas
General features
Males with VHL can develop cystadenomas in the epididy-
mis. They may arise unilaterally or bilaterally in 25–60%
of VHL males (Table 3). They are benign in nature and
do not require surgery (14, 16). These tumors typically
appear during teenage years (16). They are often asympto-
matic and incidentally detected. In 17% of patients, the
lesions are unable to palpate due to a smaller size (14).
Ultrasonography is the modality of choice in locating
these lesions. The tumors share morphologic features of
other VHL tumors (6, 14, 16).
Radiological and histological findings
Diagnosis of epididymal cystadenomas is made by palpation
and conﬁrmed with ultrasound (5, 6, 14). These lesions can be
difﬁcult to palpate due to small size; therefore, ultrasonogra-
phy is the modality of choice (14). The testes are a common
site for RCC metastasis. On gross appearance, epididymal
cystadenomas are predominantly solid but contain numerous
cysts comprised of colloid material (5, 6, 8, 14). Histologi-
cally, the cysts are lined by clear epithelium.
Management
Due to their benign nature, epididymal cystadenomas are
managed conservatively and are routinely followed with phy-
sical exam and ultrasonography. Surgery is rarely performed
to relieve compressive symptoms of these tumors.
Broad ligament cystadenomas
General features
Papillary cystadenomas are rare but found in the mesosalpinx
and the broad ligament (5, 14, 16). They may be present
unilaterally or bilaterally in women with VHL syndrome.
The incidence is unknown (Table 3). The tumor may present
as an abdominopelvic mass with symptoms of abdominal
discomfort or a painful adnexal mass (5, 14, 16).
Radiological and histological findings
Broad ligament masses may be detected by MRI of the
abdomen or pelvic ultrasound.Histologically, papillary cystade-
nomas are similar to cystadenomas of the epididymis with
respect to the prominent papillary architecture (6, 14, 16). The
core of the lesions has a ﬁbrovascular and hyaline stroma (5).
Management
These tumors are also benign and asymptomatic; thus, they
are managed conservatively. CT or ultrasonography is typi-
cally used to monitor their growth over time.
Surveillance protocols
Surveillance is not only crucial in detecting new lesions at an
early stage but also crucial for monitoring small asympto-
matic lesions. Improved understanding of clinical features,
better imaging techniques, and improvement in therapy
have decreased morbidity and mortality in patients with
VHL syndrome. Surveillance is most important in hemangio-
blastomas, RCCs, and pheochromocytomas as they most
often result in severe disability or death. Table 2 summarizes
the recommendations made by the VHL Alliance in conjunc-
tion with their Medical Advisory Board.
Figure 4. (A) Axial CT images of the abdomen with contrast
show a mass in the head of the pancreas (white arrow) in a
patient with abnormal gastrin levels clinically. (B) SPECT-CT
images of a patient after administration of In-111-octreoscan
show abnormal uptake in the pancreatic head mass
(dashed white arrow). (C) Low-power- and (D) high-power-
hematoxylin-eosin staining showing uniform neuroendocrine
cells.
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Genetic counseling
For patients with at-risk pregnancies in which at least one
of the parents has known VHL syndrome, genetic diagnosis
and subsequent counseling should be made available for
better understanding of the disease (26). Approximately
80% of patients diagnosed with VHL have one affected par-
ent. About 20% of individuals are without a positive family
history and have a de novo pathogenic variant. Genetic test-
ing is recommended for parents of an individual/proband
with a de novo pathogenic variant (19). If the pathogenic var-
iant in the proband is not known, screening for retinal lesions
and abdominal ultrasound should be offered to the parents at
the very minimum. Family history may appear to be negative
for a number of reasons, such as the early death of a parent
or reduced penetrance. Consequently, a purported negative
family history cannot be conﬁrmed without proper genetic
counseling performed on both parents of the affected indivi-
dual. The risk of VHL to other family members, such as
the siblings of the proband, depends on the status of the
proband’s parents. Among patients with somatic mosaicism,
the risk to offspring depends on whether the germ tissue
carried the mutation. Since it is difﬁcult to determine clini-
cally, patients with documented mosaicism should be coun-
seled regarding the risk. Families should keep in mind that
the best time to determine genetic risk of VHL and establish
prenatal testing is before a pregnancy. Genetic counseling,
which includes an explanation of potential risk to offspring
and reproductive options, is appropriate for young adult
patients who are affected or at risk.
Conclusion
VHL is a multisystem cancer syndrome with common
manifestations affecting the CNS and several visceral organs.
Management of VHL syndrome is complex and requires
input from various specialties. With advances in genetic test-
ing, identiﬁcation of mutations in affected individuals is read-
ily accomplished, leading to an early intervention to reduce
morbidity and mortality. Routine surveillance for common
VHL manifestations is used to monitor disease progression
and help guide treatment for tumors that can potentially
metastasize. Surgical resection of hemangioblastomas in
VHL has been shown to be effective with long-lasting
outcomes. As VHL has many endocrine manifestations,
patients require regular follow-ups and interventions after
undergoing treatment. With advances in understanding the
molecular biology of VHL syndrome, several therapies
targeting downstream targets of VHL, such as VEGF, are
currently available in treating patients with common manifes-
tations such as RCC. The future challenge is to understand
precise molecular changes and develop new therapies for
the various manifestations of the syndrome.
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